Pliant Therapeutics, Inc. (PLRX)

NASDAQ: PLRX · Real-Time Price · USD
2.720
+0.115 (4.41%)
At close: Feb 12, 2025, 4:00 PM
2.710
-0.010 (-0.37%)
After-hours: Feb 12, 2025, 6:38 PM EST
4.41%
Market Cap 165.52M
Revenue (ttm) n/a
Net Income (ttm) -201.68M
Shares Out 60.85M
EPS (ttm) -3.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,488,077
Open 2.580
Previous Close 2.605
Day's Range 2.430 - 2.738
52-Week Range 2.430 - 18.000
Beta 1.04
Analysts Buy
Price Target 14.86 (+446.32%)
Earnings Date Feb 26, 2025

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver f... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 2020
Employees 158
Stock Exchange NASDAQ
Ticker Symbol PLRX
Full Company Profile

Financial Performance

In 2023, Pliant Therapeutics's revenue was $1.58 million, a decrease of -83.69% compared to the previous year's $9.69 million. Losses were -$161.34 million, 30.8% more than in 2022.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is $14.86, which is an increase of 446.32% from the latest price.

Price Target
$14.86
(446.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

2 hours ago - GlobeNewsWire

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Pliant Therapeutics, Inc. PLRX stock is trading lower on Monday.

2 days ago - Benzinga

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed

5 days ago - GlobeNewsWire

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of ...

21 days ago - GlobeNewsWire

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company a...

3 months ago - GlobeNewsWire

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: P...

4 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the...

6 months ago - GlobeNewsWire

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therape...

6 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D., Chi...

6 months ago - GlobeNewsWire

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics fo...

8 months ago - GlobeNewsWire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therape...

8 months ago - GlobeNewsWire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ther...

9 months ago - GlobeNewsWire

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen  as measured by PET imaging, compared to an increase on placebo

9 months ago - GlobeNewsWire

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeu...

10 months ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates  bexotegrast development in IPF

10 months ago - GlobeNewsWire

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX),...

11 months ago - GlobeNewsWire

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Acceptance by European Union and other global health authorities of the pivotal, adaptive Phase 2b/3 trial will significantly shorten bexotegrast's time to Phase 3 data

1 year ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN FRA...

1 year ago - GlobeNewsWire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the...

1 year ago - GlobeNewsWire

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with  no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts

1 year ago - GlobeNewsWire

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is sche...

1 year ago - GlobeNewsWire

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation

1 year ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification...

1 year ago - GlobeNewsWire

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the...

1 year ago - GlobeNewsWire

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the...

1 year ago - GlobeNewsWire